Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799569 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1SIRT6SIRT1ITGB3 | |
| SCHEMBL22800098 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1SIRT6SIRT1ITGB3 | |
| SCHEMBL13311784 | 0.87 | ARG1 (0.31) | ARG1ARG2 | |
| SCHEMBL17662433 | 0.86 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL11956479 | 0.86 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL16248631 | 0.86 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL27309897 | 0.86 | KISS1R (0.39) | SIRT5ALBNOD1SIRT6SIRT1 | |
| SCHEMBL13262513 | 0.84 | FOLH1 (0.40) | KDM4EALDH1A1NOD1ITGB3ITGA2B | |
| SCHEMBL13707922 | 0.81 | FOLH1 (0.41) | SIRT6SIRT1 | |
| SCHEMBL26684412 | 0.81 | ADH1B (0.35) | KDM4EALDH1A1SIRT5ALBARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230015478-A1 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | RESOLUTE BIO INC (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015478-A1 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | GLP1R, GIPR, IAPP | KDM4E 4744/4885ALDH1A1 3665/4885SIRT5 3461/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | KDM4E 3165/4885ALDH1A1 3285/4885SIRT5 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.